Molecular metabolism|2018|Coskun T et al.|636 citations
OBJECTIVE: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). METHO…
Randomized Controlled TrialAnimal Study
PMID: 30473097